Navigation Links
Gene mutation improves leukemia drug's effect
Date:6/17/2008

COLUMBUS, Ohio Gene mutations that make cells cancerous can sometimes also make them more sensitive to chemotherapy. A new study led by cancer researchers at Ohio State University shows that a mutation present in some cases of acute leukemia makes the disease more susceptible to high doses of a particular anticancer drug.

The findings, from a Cancer and Leukemia Group B clinical cooperative group study led by Dr. Clara D. Bloomfield, an internationally known AML specialist at the Ohio State University Comprehensive Cancer Center, could change how doctors manage these patients.

The research is published online in the June 16 issue of the Journal of Clinical Oncology with an accompanying editorial.

The retrospective study shows that people with acute myeloid leukemia (AML) whose leukemic cells have mutations in the RAS gene are more likely to be cured when treated after remission with high doses of the drug cytarabine.

It also suggests that testing for RAS mutations might help doctors identify which AML patients should receive high-dose cytarabine as their post-remission therapy.

"This appears to be the first example in AML of a mutation in an oncogene that favorably modifies a patient's response to the dose of a routinely used chemotherapeutic drug," Bloomfield says.

"If confirmed, AML patients in the future will likely be screened for RAS mutations, and those who have one may get high-dose cytarabine for post-remission therapy rather than a stem-cell transplant."

Typically, people with newly diagnosed AML are treated first with drugs intended to drive the disease into complete remission, Bloomfield says. When that is achieved, patients are given additional chemotherapy, such as high-dose cytarabine, or more aggressive therapy, such as a stem cell transplant, to prevent relapse and to cure the malignancy.

But high-dose cytarabine is the better therapy for some patients, and the findings of this study may enable doctors to identify those individuals.

The research analyzed the outcome of 185 AML patients age 60 or less who had achieved complete remission following initial therapy. Thirty-four of the patients (18 percent) had mutations in the RAS gene, and of these, 22 received high-dose cytarabine and 12 received the drug at low dose.

The high-dose patients with RAS mutations had the lowest relapse rate 45 percent experienced disease recurrence after an average 10-year follow-up compared with 68 percent for those with normal RAS genes.

"That means fifty-five percent of patients with RAS mutations were cured compared with 32 percent of high-dose patients with normal RAS," Bloomfield says.

Of patients who received low doses of the drug, all those with the mutations relapsed, as did 80 percent of those with normal RAS genes.

"These data strongly suggest that mutations in RAS influence the response of AML patients to high-dose cytarabine, and they support the use of these mutations as biomarkers for this therapy," says Bloomfield, who is also a Distinguished University Professor, the William G. Pace III Professor in Cancer Research and an OSU Cancer Scholar.


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Gene Mutations May Cause Rare Neonatal Diabetes
2. Gene Mutation Linked to Parkinsons Disease
3. Research shows how genetic mutation causes epilepsy in infants
4. Gene Mutation Key to Infertility in Male Mice
5. Overlooked Mutation Can Spur HIV Drug Resistance
6. OHSU Cancer Institute researcher discovers what fuels certain cancer mutation
7. Breast cancer gene mutation more common in Hispanic, young black women, Stanford/NCCC study finds
8. BRCA1 Mutation Prevalent Among Hispanic, Younger Black Women
9. Ashkenazi ovarian cancer patients with BRCA mutations live longer than those with normal gene
10. BRCA Mutations Dont Raise Breast Cancer Risk Equally
11. Genetic Mutations Boost Prostate Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: A ... God in congregations across the United States. “The Communion of Saints” is ... who has served congregations in seven states throughout his long career of devotion ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center PA ... Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite 440, ... newest location will provide patients living in the north Houston area (The Woodlands, Conroe, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is revolutionizing ... a huge impact on businesses and individual consumers alike. Laboratories can maximize their ... a value anywhere from $4 trillion to $11 trillion dollars by the year 2025. ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Valve Devices Market: Analysis By Procedure, Replacement Procedure By Technique, Repair ... their offering. ... Global Heart Valve Devices Market is forecasted to grow at a ... heart valve devices is driven by rising aging population, growth in ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
(Date:3/23/2017)... 2017 Summary ... pipeline guide Primary Hyperoxaluria - Pipeline Review, H1 ... (Genito Urinary System And Sex Hormones) pipeline landscape. ... by recurrent kidney and bladder stones. It results ... Symptoms include blood in the urine, pain when ...
Breaking Medicine Technology: